A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Status:
Completed
Trial end date:
2012-08-07
Target enrollment:
Participant gender:
Summary
This is a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison
study to confirm the efficacy of 323U66 Sustained Release (SR) orally administered to
patients with MDD (Major Depressive Disorder) at doses level of 150 mg/day and 300 mg/day for
8 weeks based on the decrease in MADRS (Montgomery-Asberg Depression Rating Scale) total
score, and to evaluate the safety based on adverse events, clinical laboratory tests and
vital signs.